10:01 ET -- Sanofi is one of the most mentioned companies in the U.S. across all news items in the last 12 hours, according to Factiva data. Sanofi said a second phase 3 trial of Dupixent met its primary endpoint with what the company said was overwhelming efficacy. Sanofi said its Notus trial confirmed positive published results from the Phase 3 Boreas trial. The Notus trial found that the treatment "significantly reduced exacerbations," and that treatment with Dupixent led to rapid and significant improvements in lung function for patients with the life-threatening respiratory disease COPD. Dow Jones & Co. owns Factiva. (chris.wack@wsj.com)

 

(END) Dow Jones Newswires

November 27, 2023 10:16 ET (15:16 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Sanofi (EU:SAN)
Graphique Historique de l'Action
De Fév 2024 à Mar 2024 Plus de graphiques de la Bourse Sanofi
Sanofi (EU:SAN)
Graphique Historique de l'Action
De Mar 2023 à Mar 2024 Plus de graphiques de la Bourse Sanofi